Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/107737SARS-CoV-2 DETECTION KIT AND SARS-CoV-2 DETECTION METHOD
WO 27.05.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/JP2021/041983 Applicant FUJIFILM CORPORATION Inventor UJIHARA Dai
The present invention addresses the problem of providing a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method that enable the detection of SARS-CoV-2 in a simple manner and with higher sensitivity. The present invention provides a SARS-CoV-2 detection kit for specifically detecting a nucleocapsid protein (NP) contained in a biological sample, the SARS-CoV-2 detection kit comprising at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), wherein the antibody includes at least one antibody of which the subclass is IgG2b, and the kit includes a first container that receives a silver-containing compound, and a second container that receives a reducing agent that can reduce silver ions.
2.WO/2022/108951USE OF ANNEXIN V TO IMPROVE THE PURITY, SOLUBILITY AND LONG-TERM STABILITY OF PHAGE SUSPENSIONS
WO 27.05.2022
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2021/059580 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor BLANKENBERG, Francis Gerard
Methods are provided for the prevention of aggregation, simple purification stabilization and preservation of phage preparations for the use of treating bacterial infections.
3.WO/2022/109241IMPROVED AAV PRODUCTION USING POTASSIUM CHLORIDE
WO 27.05.2022
Int.Class C12N 15/864
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
864Parvoviral vectors
Appl.No PCT/US2021/060046 Applicant UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED Inventor CLEMENT, Nathalie
Provided herein are methods of improving rAAV production in mammalian cells via the manipulation of a concentration of potassium chloride present in the media in which the mammalian cells are cultured and/or in which the rAAV particles are produced. The concentration of potassium chloride present in such media may be manipulated by, for example, supplementing a base medium with additional potassium chloride either before, at the same time as, or after the cells are contacted (e.g., infected) with one or more viral vectors (e.g., recombinant Herpes Simplex Virus (rHSV) vectors). Some embodiments of the present invention further contemplate supplementing the base medium with additional potassium chloride and sodium chloride in combination.
4.WO/2022/107705NEW GENE RECOMBINANT VACCINIA VIRUS AND UTILIZATION THEREOF
WO 27.05.2022
Int.Class C12N 15/24
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
19Interferons; Lymphokines; Cytokines
24Interleukins
Appl.No PCT/JP2021/041825 Applicant NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY Inventor NAKAMURA Takafumi
Provided are a vaccinia virus into which a therapeutic gene has been introduced as an exogenous gene, and a therapeutic composition containing said vaccinia virus. The vaccinia virus comprises at least one immune regulating gene as an exogenous gene.
5.WO/2022/109430SUSTAINED RELEASE INACTIVATED VACCINES
WO 27.05.2022
Int.Class A61K 39/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
Appl.No PCT/US2021/060407 Applicant CASTOR, Trevor, P. Inventor CASTOR, Trevor, P.
The present invention is directed to methods and apparatus for creating a sustained release pathogen vaccine for COVID-19, influenza, HIV and other infectious human and animal viruses and pathogens using supercritical, critical, or near-critical fluids with or without polar cosolvents for simultaneously inactivating virions and pathogens, and encapsulating the inactivated virions and pathogens in biodegradable polymer nanospheres for administration to a patient. The present invention continuously inactivates SARS-CoV-2, influenza, HIV and other infectious human and animal viruses and pathogens, and nanoencapsulates the inactivated virions and pathogens in biodegradable polymer nanospheres to provide a safe and effective sustained-release vaccine, especially for the frail and elderly.
6.WO/2022/107793IMMORTALIZED PIG-FETUS SMALL-INTESTINAL MACROPHAGES
WO 27.05.2022
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Appl.No PCT/JP2021/042171 Applicant NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION Inventor TAKENOUCHI Takato
Attempts have been made to isolate macrophages from the small intestine of approximately one-month-old pigs and immortalize the macrophages, but microbial contamination was severe and isolation of macrophages from the porcine small intestine was not successful even when medium containing antibiotics and antifungals was used. However, it was discovered that the contamination is suppressed and primary culture of macrophages is possible if the small intestine of a pig fetus is used. Furthermore, it was clarified that the small-intestinal macrophages of the primary culture can be immortalized by causing SV40 large T antigen and telomerase reverse transcriptase to be expressed, and it became possible to provide a cell line of subculturable porcine small-intestinal macrophages.
7.WO/2022/109503RECOMBINANT ONCOLYTIC VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS
WO 27.05.2022
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
Appl.No PCT/US2021/060669 Applicant DEVACELL, INC. Inventor ORTAC, Inanc
Provided herein are recombinant viruses and artificially coated delivery systems, and methods of use.
8.WO/2022/108120MODIFIED HTERT PROMOTER FOR REGULATING CANCER CELL-SPECIFIC GENE EXPRESSION AND ANTI-TUMOR ADENOVIRUS CONTAINING SAME
WO 27.05.2022
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/KR2021/014180 Applicant CURIGIN CO.,LTD. Inventor PARK, Seong Hoon
The present invention relates to a modified hTERT promoter for regulating cancer cell-specific gene expression and an oncolytic adenovirus comprising same. The modified hTERT promoter of the present invention increases the cancer-specific transcriptional activity of a target gene compared to the case where a wild-type hTERT promoter is used, and when the modified hTERT promoter is used for an oncolytic adenovirus, the tumor-killing effect is excellent compared to the case where an adenovirus is prepared using the wild-type hTERT promoter.
9.WO/2022/103929NUCLEIC ACIDS, PROTEINS, AND VACCINES OF SARS-COV-2
WO 19.05.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/058929 Applicant CITY OF HOPE Inventor KWAK, Larry, W.
Provided herein are, inter alia, SARS-CoV-2 spike (S) proteins; nucleic acids and plasmids encoding the proteins; vaccines and pharmaceutical compositions comprising the proteins, nucleic acids, or plasmids; methods for treating or preventing COVID-19; and methods for increasing immunity or providing acquired immunity to SARS-CoV in a subject.
10.20220154150ARTIFICIAL VIRUS PRESENTING CELLS
US 19.05.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No 17550958 Applicant Diagnologix, LLC Inventor Yu-Tsueng LIU

A method for ex vivo transduction of biomolecules from viruses, viral vectors or virus-like particles into target cells and microbubbles for use in this method. A quantity of viruses, viral vectors or virus-like particles and target cells are bound to flexible lipid shell microbubbles, bringing these into close proximity to each other that allows viral transduction, transferring biomolecules from the viruses, viral vectors or virus-like particles into the target cells while the viruses, viral vectors or virus-like particles and the target cells are bound to the microbubbles.